Respiri Limited signs joint development agreement with Phenix Health, surges 50%

By Trevor Hoey. Published at Apr 14, 2020, in ASX Biotechs

Shares in Respiri Limited (ASX:RSH), an eHealth SaaS company supporting respiratory health management, hit a high of 11.5 cents on Tuesday, representing a 55% rise relative to its previous closing price of 7.4 cents.

The sharp uptick in the company’s share price was under the highest volumes traded in 2020, underlining the significance of the news released shortly after the market opened.

The signing of a Joint Development Agreement (JDA) with Phenix Health Pty Ltd, an Australian based health workflow designer for virtual healthcare settings (telemedicine) triggered substantial investor interest.

Under the terms of the JDA, Respiri will work to ensure that the wheezo eHealth SaaS monitoring platform is integrated into the Phenix proprietary telehealth platform, patient dashboards and asthma management plans.

Respiri’s world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation.

The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Phenix to provide pre-diagnosed patients

Phenix will we be responsible for providing patients already diagnosed with asthma the option of using wheezo to help monitor their condition, providing healthcare beyond the clinic setting.

Mr Marjan Mikel, managing director of Respiri said, “The joint development agreement with Phenix underscores our commitment to patients with asthma and related respiratory disease in Australia during the COVID-19 pandemic.

‘’By increasing awareness and access through Phenix’s leading telehealth platform, innovative technology solutions such as wheezo will support more effective monitoring of a patient’s underlying condition to better empower patients and their treating physicians in the management of their condition during this critical period and beyond.”

Ms Gillian Alexis, Chief Executive of Phenix Health commented that the group was keen to pursue other initiatives with Respiri in saying, “This ground-breaking partnership represents an improvement in quality of life for the world’s 340 million asthma sufferers and will provide primary care providers as well as respiratory specialists with new key insights to help patients manage their asthma proactively.

‘’We look forward to evolving new longitudinal models of care with Respiri that are focused on measurable outcomes by complementing traditional brick and mortar services.”

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X